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Belatacept is an intravenously infused selective T cell costimulation blocker approved for 
preventing organ rejection in renal transplant recipients aged ≥18 years. This phase I trial 
examined the pharmacokinetics and pharmacodynamics (percentage CD86 receptor oc‐
cupancy [%CD86RO]) of a single dose of belatacept (7.5 mg/kg) administered to kidney 
transplant recipients aged 12‐17 years receiving a stable calcineurin inhibitor–based im‐
munosuppressive regimen. Nine adolescents (mean age 15.1 years) who were seroposi‐
tive for Epstein‐Barr virus were enrolled; all completed the 6‐month study. 
Pharmacokinetics suggested relatively low variability of exposure (coefficients of varia‐
tion for maximum observed serum concentration [Cmax] and area under the serum con‐
centration‐time curve from time zero extrapolated to infinity [AUC0‐INF] were 20% and 
25%, respectively). Mean half‐life (T1/2) occurred 7.2 days postinfusion. Belatacept total 
body clearance was 0.48 mL/h/kg, and volume of distribution at steady‐state (Vss) was low 
at 0.09 L/kg. Compared with historical data from healthy adult volunteers administered a 
single dose of belatacept 10 mg/kg and adult kidney transplant recipients administered 
multiple doses of belatacept 5 mg/kg, pharmacokinetic values for adolescents were simi‐
lar, indicating consistency across adolescent and adult populations. Mean %CD86RO in‐
creased with increasing belatacept concentration, indicating a direct relationship between 
pharmacokinetics and pharmacodynamics. Four patients reported 7 serious adverse 
events; none was considered related to belatacept. These data will inform belatacept 
dose selection in future studies of adolescent kidney transplant recipients.
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1  | INTRODUC TION
Adolescent renal transplant recipients aged 13‐17 years have the 
poorest long‐term graft‐survival rates (5‐year) of any age group 
≤65 years,1 irrespective of whether they have been transplanted 
with a kidney from a living or deceased donor.1,2 Regardless of the 
age at which transplantation has occurred, pediatric renal transplant 
recipients are most vulnerable to graft loss during adolescence/
young adulthood.3,4 Nonadherence with oral immunosuppression 
has been identified as a major contributor to graft loss among ado‐
lescents.5,6 In addition, chronic use of calcineurin inhibitors (CNIs) is 
associated with chronic allograft injury, including tubulointerstitial 
fibrosis and chronic allograft dysfunction,7‐12 and cardiovascular and 
metabolic adverse events (AEs).13
Belatacept is an intravenously infused soluble fusion protein that 
selectively blocks CD86‐CD28 costimulation between antigen‐pre‐
senting cells and T cells (Figure S1).14 Ligation of CD28 with CD86 is 
an important stimulatory signal for CD28‐bearing T cells; belatacept 
blocks ligation of CD28 by CD86, resulting in T cell quiescence.14 
Belatacept is approved in the United States, the European Union, 
and other countries, for preventing renal transplant rejection in 
adults who are seropositive for the Epstein‐Barr virus. As a result 
of belatacept being intravenously infused under medical super‐
vision and the lack of nephrotoxicity,15,16 belatacept may improve 
adherence and clinical outcomes in adolescent kidney transplant re‐
cipients. However, belatacept is currently indicated for use only in 
adults. Because the pharmacokinetics of numerous immunosuppres‐
sive agents have been shown to differ between pediatric and adult 
patients,17,18 the present phase I study was undertaken to assess the 
pharmacokinetics and pharmacodynamics of a single intravenous in‐
fusion of belatacept administered to renal transplant recipients aged 
12‐17 years.
2  | MATERIAL S AND METHODS
2.1 | Study design
In this multicenter (5 sites), open‐label, phase I study 
(NCT01791491), kidney transplant recipients aged 12‐17 years, 
seropositive for Epstein‐Barr virus, received a single intravenous 
infusion of belatacept of 7.5 mg/kg over 30 minutes. Eligible 
patients had been transplanted with a living or deceased donor 
kidney ≥6 months before enrollment and were receiving a sta‐
ble regimen of CNI‐based immunosuppression. Patients contin‐
ued maintenance immunosuppression per local practice without 
change following belatacept infusion. Under the original protocol, 
patients were to continue to receive mycophenolate mofetil or 
mycophenolic acid with concomitant corticosteroids. However, 
following a protocol amendment, maintenance immunosuppres‐
sion with corticosteroids became optional (thus, only 8 of the 
9 adolescents treated in this study were receiving maintenance 
corticosteroids). Study participants also had an estimated GFR 
(eGFR) ≥45 mL/min/1.73 m2 per the updated Schwartz formula19 
and urine albumin‐to‐creatinine ratio <56.5 mg/mmol (<0.5 mg 
albumin/mg creatinine). Individuals with a history of any treated 
or biopsy‐proven acute rejection in the 3 months before enroll‐
ment were excluded, as were individuals with any active infection. 
The study conformed to Good Clinical Practice guidelines and 
Declaration of Helsinki principles. The protocol was approved by 
the institutional review board/ethics committee at the participat‐
ing centers.
2.2 | Dose selection
Because belatacept had not been previously studied in adolescents, 
initial dose selection for this age group was based on simulations 
that extrapolated data from an adult population pharmacokinetic 
model20 to adolescents.21 The dose selected for use in adolescents 
was that necessary to achieve steady‐state trough (Cmin) concentra‐
tions comparable to those observed in stable adult renal transplant 
recipients participating in a phase II study.22,23 Based on the assump‐
tion that belatacept exposure at Cmin is highly correlated with re‐
ceptor occupancy, which then drives pharmacologic activity,20 and 
because it was expected that belatacept clearance would increase 
with decreasing age (due to generally higher metabolic rates in chil‐
dren), we reasoned that a higher belatacept dose was likely needed 
for adolescents to achieve Cmin similar to that observed in adults. 
Thus, belatacept 7.5 mg/kg was selected as the dose to be adminis‐
tered to adolescents.
2.3 | Endpoints
The primary endpoint was evaluation of single‐dose pharmacokinet‐
ics (maximum observed serum concentration [Cmax], time of maxi‐
mum observed serum concentration [Tmax], area under the serum 
concentration‐time curve from time zero extrapolated to infinity 
[AUC0‐INF], area under the serum concentration‐time curve from 
time zero to the time of the last quantifiable concentration [AUC0‐T], 
half‐life [T1/2], total body clearance [CLT], and volume of distribu‐
tion at steady‐state [Vss]). Cmin can only be evaluated under multi‐
ple‐dose, steady‐state conditions (and IM103‐144 was a single‐dose 
study). Thus, Cmin was assessed through model‐based simulations 
and not measured directly. Blood was collected for the evaluation of 
pharmacokinetics on day 1 (predose, 0.5, and 2 hours after the start 
of the infusion) and on days 8, 15, 29, and 57; samples were then 
analyzed at a central facility (Pharmaceutical Product Development, 
Richmond, VA) using a previously validated enzyme‐linked immuno‐
sorbent assay (ELISA).
Secondary endpoints included the percentage of CD86 recep‐
tor occupancy (%CD86RO; pharmacodynamics) under belatacept 
administration and the relationship between pharmacokinetics 
and pharmacodynamics. Blood was collected for the evaluation of 
the %CD86RO on days 1, 29, and 57 and centrally assessed (Q2 
Solutions, Morrisville, NC) using a flow cytometry–based CD86 re‐
ceptor competition assay. AEs were recorded up to day 57, and seri‐
ous AEs were recorded up to month 6 (final visit). AEs were mapped 
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to terms from the Medical Dictionary for Regulatory Affairs ver‐
sion 19.0.
2.4 | Pharmacokinetics
Pharmacokinetic data were calculated via Phoenix version 1.4, with 
individual patient pharmacokinetic parameter values derived by 
noncompartmental methods. Serum concentration‐time data and 
nominal times were used for the generation of mean serum concen‐
tration‐time plots and summary statistics.
Cmax and Tmax were recorded directly from experimental observa‐
tions. The terminal log‐linear phase of the concentration‐time curve 
(without a weighting factor) was identified by least‐squares linear 
regression of ≥3 data points (excluding Tmax) that yielded an adjusted R
2 
value. T1/2 was calculated as ln2/λ, where λ was the absolute value of the 
slope of the terminal log‐linear phase. AUC0‐T was calculated by mixed 
log‐linear trapezoidal summations. AUC0‐INF was estimated by summing 
AUC0‐T and the extrapolated area, which was computed by the quotient 
of the last observable concentration and λ. CLT was calculated by divid‐
ing the total dose administered by AUC0‐INF. Vss after intravenous dosing 
was calculated by dividing the product of dose × mean residence time 
(MRT) by AUC0‐INF, where MRT was derived by dividing the area under 
the moment curve by the corresponding AUC0‐INF value. We then com‐
pared numerically the pharmacokinetic data derived from adolescents 
administered a single dose of belatacept of 7.5 mg/kg with historical 
data derived from healthy adult volunteers administered a single dose of 
Patients (N = 9)
Mean age (range), y 15.1 (13‐17)
Female, n (%) 4 (44.4)
Race, n (%)
Caucasian 5 (55.6)
Black/African American 4 (44.4)
Mean weight (range), kg 59.1 (37.6‐103.5)
Mean BMI (range), kg/m2 23.8 (16.4‐39.0)
Prior number of kidney transplants, n (%)
0 5 (55.6)
1 4 (44.4)
Categorized highest PRA, n (%)
<20% 9 (100.0)
≥20% 0 (0)
Reported cause of ESRD, n (%)
Congenital renal hypodysplasia 2 (22.2)
Glomerular disease 2 (22.2)
Congenital obstructive uropathy 1 (11.1)
Chronic tubulointerstitial disease with glomerulosclerosis 1 (11.1)
Nephronophthisis 1 (11.1)
Renal artery stenosis 1 (11.1)
Unknown 1 (11.1)
HLA mismatches, n (%)
1 1 (11.1)
2 0 (0)
3 2 (22.2)
4 2 (22.2)
5 3 (33.3)
6 1 (11.1)
EBV seropositive, n (%) 9 (100.0)
CMV seropositive, n (%) 4 (44.4)
Recipient of a living donor kidney, n (%) 6 (66.7)
Mean estimated GFR,a mL/min/1.73 m2 (range) 73.1 (55.3‐106.8)
CMV, cytomegalovirus; EBV, Epstein–Barr virus; ESRD, end‐stage renal disease; PRA, panel reactive 
antibody.
aPer the updated Schwartz formula. 
TA B L E  1   Baseline demographics and 
disease characteristics
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belatacept of 10 mg/kg and adult kidney transplant recipients adminis‐
tered multiple doses of belatacept of 5 mg/kg.24
2.5 | Pharmacodynamics
As previously described,20 the %CD86RO was calculated at baseline 
and at each postinfusion time point. The relationship between phar‐
macokinetics and pharmacodynamics was assessed using Phoenix ver‐
sion 1.4, with simultaneous assessment of belatacept concentration 
and CD86RO. The maximal CD86RO by belatacept was calculated by 
multiplying the quotient of Emax/E0 by 100%, where Emax is the maximal 
decrease in free CD86 receptor level and E0 is the baseline free CD86 
receptor level when drug concentration is 0. A maximum effect (Emax) 
model was used to describe the relationship between the percentage 
of CD86 receptor occupancy and belatacept concentration.
2.6 | Statistical analysis
Data from nine adolescents would provide 97% confidence that the 
point estimate of the geometric mean would be within 20% of the 
true value for Cmax and within 20% of the true value for AUC0‐INF, as‐
suming that Cmax and AUC0‐INF values were log‐normally distributed 
with coefficients of variation of 27% and 28%, respectively.
3  | RESULTS
3.1 | Patients
Nine adolescent kidney transplant recipients received a single 
intravenous infusion of belatacept 7.5 mg/kg, and all continued in 
the study to day 57 and completed the follow‐up visit at month 6. 
Baseline demographics and disease characteristics are summarized 
in Table 1. The actual mean (standard deviation [SD]) dose of belata‐
cept administered was 7.4 (0.3) mg/kg over a mean (SD) duration of 
infusion of 29.9 (1.3) minutes.
3.2 | Pharmacokinetics
Pharmacokinetic data were available for all 9 study participants 
and are summarized in Table 2. The single‐dose pharmacokinetics of 
belatacept in adolescent renal transplant recipients demonstrated 
low variability in the exposure parameters Cmax and AUC0‐INF, with 
coefficients of variation of 20% and 25%, respectively. Median Tmax 
was 0.73 (range 0.45‐2.05) hours, and mean T1/2 was 7.2 days after 
single‐dose intravenous infusion. The Vss of belatacept was 5.26 L 
(0.09 L/kg when adjusted for weight)—consistent with previous ob‐
servations in adults that the distribution of belatacept is restricted to 
the extracellular fluid volume.20 Pharmacokinetic values from ado‐
lescent kidney transplant recipients who received a single belatacept 
intravenous infusion (7.5 mg/kg) were similar to historical values de‐
rived from healthy adult volunteers who received a single belatacept 
intravenous infusion (10 mg/kg) and adult kidney transplant recipi‐
ents who received multiple intravenous doses of belatacept (5 mg/
kg) (Table 2).24
3.3 | Pharmacodynamics
Pharmacodynamic data were available for 7 study participants on 
day 1 (0.5 hours) and day 29, and for 5 study participants on day 
57. Mean CD86RO was highest at hour 0.5 of day 1, with mean (SD) 
CD86RO of 94.7% (4.0) at hour 0.5 of day 1, 78.0% (11.0) at day 29, 
and 51.5% (43.3) at day 57.
TA B L E  2   Pharmacokinetic parameters derived from adolescent kidney recipients administered a single dose of belatacept 7.5 mg/kg, 
healthy adult volunteers administered a single dose of belatacept 10 mg/kg, and adult kidney transplant recipients administered multiple 
doses of belatacept 5 mg/kg
Adolescent kidney transplant recipients Healthy adult volunteersa
Adult kidney transplant 
recipientsa
N = 9 N = 15 N = 14
Belatacept
Dose 7.5 mg/kg 10 mg/kg 5 mg/kg
Dosing frequency Single Single Multiple
Cmax, μg/mL 151 (20) 300 (26) 139 (20)
T1/2, h 173 (47) 235 (29) 197 (29)
CLT, mL/h/kg 0.48 (27) 0.39 (18) 0.51 (27)
Vss, L/kg 0.09 (30) 0.09 (22) 0.12 (25)
AUC, μg·h/mL 15 407 (25)b 26 398 (20)b 14 090 (27)c
AUC0‐INF, area under the serum concentration‐time curve from time zero extrapolated to infinity; AUC0‐T, area under the serum concentration‐time 
curve from time zero to the time of the last quantifiable concentration; CLT, total body clearance; Cmax, maximum observed serum concentration; T1/2, 
half‐life; Vss, volume of distribution at steady‐state.
Data are mean (coefficient of variation expressed as a percentage).
aData derive from the Nulojix package insert, 2017. 
bAUC0‐INF after a single dose. 
cAUC0‐T after multiple doses, where “T” is equivalent to 4 weeks. 
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3.4 | Relationship between pharmacokinetics and 
pharmacodynamics
The highest CD86RO was observed at high belatacept concen‐
trations and decreased as belatacept concentrations declined 
(Figure 1).
3.5 | Safety
During the protocol‐specified, 57‐day postdose safety monitoring 
period, 3 patients reported 7 AEs. Only headache occurred in more 
than one patient (n = 2). One patient experienced 3 AEs that were 
considered related to belatacept (asthenia [day 2], vomiting [day 6], 
upper abdominal pain [day 6]); all 3 events were graded as mild. During 
the protocol‐specified monitoring period through month 6, 4 patients 
reported 7 serious AEs, all of which were considered by the investigator 
to be unrelated to belatacept. There were no reports of biopsy‐proven 
acute rejection, graft loss, or death during the protocol‐specified 6‐
month follow‐up period. Episodes of renal function deterioration were 
reported for 3 patients between 191 and 663 days following a single 
intravenous dose of belatacept. Each was associated with an AE (acute 
gastroenteritis or acute pyelonephritis/urinary tract infection), and all 
were considered by the investigator to be unrelated to belatacept.
4  | DISCUSSION
The pharmacokinetic data derived from this phase I study of 
adolescent renal transplant recipients demonstrate relatively 
low variability of exposure to intravenously infused belatacept 
(percentage coefficients of variations for Cmax and AUC0‐INF were 
20% and 25%, respectively). In addition, mean values for T1/2, CLT, 
and Vss in adolescent kidney transplant recipients were comparable 
to historical values from healthy adult volunteers and adult kidney 
transplant recipients, indicating consistency across adolescent 
and adult populations. To identify a dosing regimen that matches 
the belatacept exposures in adult kidney transplant patients, a 
population pharmacokinetic model was developed using data from 
the 9 adolescent patients in this study. Utilizing this model and the 
pharmacokinetic parameters and variability generated, simulations 
were performed to assess various belatacept dosing regimens in a 
virtual population of adolescent kidney transplant recipients. This 
virtual population was varied based on the distributions of body 
weight by age and gender derived from the National Health and 
Nutrition Examination Survey database (unpublished data). The 
simulations from this modeling work indicate that in adolescent 
renal allograft recipients, a belatacept dose of 7.5 mg/kg will provide 
a level of exposure comparable to adult kidney transplant recipients 
receiving belatacept 5 mg/kg.25
Saturation of the CD86 receptor has been shown to correlate 
with inhibition of the alloimmune response14 and presumably a re‐
duced risk of acute rejection episodes. High levels of CD86RO were 
observed in this study (94.7% on day 1). In adults, 94% occupancy of 
CD86 was observed on day 5.14,20 Thus, the extent of CD86RO mea‐
sured in adolescent kidney transplant recipients was comparable to 
that observed in adult renal transplant recipients. We observed a 
pharmacologic relationship between pharmacokinetics (drug con‐
centration) and pharmacodynamics (%CD86RO), such that satura‐
tion of the CD86 receptor increased with increasing concentrations 
of belatacept. This relationship was also observed in adults and was 
best described using an Emax model.
20 No new belatacept‐related 
safety events were reported in any patient during the protocol‐spec‐
ified 6‐month follow‐up period. The data from this phase I study will 
be used to inform belatacept dose selection in future studies of ado‐
lescent kidney transplant recipients.
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